Saturday, December 3, 2022 | Back issues
Courthouse News Service Courthouse News Service

FTC OKs Teva-Barr Pharma Merger

WASHINGTON (CN) - Teva Pharmaceuticals will buy rival generic drugmaker Barr Pharmaceuticals for $8.9 billion, but the merger partners will have to sell assets in 29 U.S. markets to competitors Watson and Qualitest Pharmaceuticals, the FTC said in a settled complaint. Teva and Barr will have to sell assets that include generic drugs used to treat acid reflux, cancer, bacterial infections, diabetes and depression.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.